In a significant move, CBC Group, Asia’s largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its portfolio company, Hasten Biopharmaceutical, has successfully acquired the asset rights of 14 branded products from South Korean biopharmaceutical company, Celltrion. The deal price remains undisclosed. According to the agreement, Hasten Biopharmaceutical will hold the Marketing Authorization Holder […]
Harbour BioMed (HKEX: 02142), a prominent global biopharmaceutical company, has announced the resubmission of the Biologics License Application (BLA) for batoclimab (HBM9161) to the National Medical Products Administration (NMPA) of China. This resubmission is a significant step toward the potential approval and commercialization of batoclimab for the treatment of generalized myasthenia gravis (gMG), a debilitating […]
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has officially declined the latest acquisition proposal from Future Pak, LLC (FP), citing substantial undervaluation and significant risk. The offer, ranging from $7.25 to $7.75 per share in cash, coupled with certain Contingent Value Rights (CVRs), was unanimously rejected by Vanda’s Board of Directors after thorough consultations with independent financial […]
Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical company, has successfully closed an oversubscribed Series A financing round, securing $100 million. This significant milestone was led by ARCH Venture Partners and Sofinnova Investments, in collaboration with Third Rock Ventures and Seaport founder PureTech Health. This financial injection is earmarked for the accelerated development of Seaport’s clinical-stage pipeline […]
Ascentage Pharma (6855.HK), a prominent global biopharmaceutical firm, recently unveiled the latest preclinical study results for its innovative drug candidates at the American Association of Cancer Research Annual Meeting (AACR 2024) held in San Diego, California. This pivotal revelation underscores the company’s continued dedication to pioneering novel therapies for cancer, chronic hepatitis B (CHB), and […]
InnoCare Pharma, listed on both the Hong Kong Stock Exchange (HKEX: 09969) and the Shanghai Stock Exchange (SSE: 688428), along with ArriVent BioPharma, Inc. (Nasdaq: AVBP), has announced the commencement of a Phase 1b clinical study in China. This study marks the first time a patient has been dosed with a novel therapeutic combination targeting […]
In a significant development for the treatment of anemia related to chronic kidney disease (CKD) in dialysis patients, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pioneering biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of Vafseo (vadadustat) Tablets. This approval marks a crucial milestone in providing an alternative and innovative treatment option for […]
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic move in the biopharmaceutical sector focused on the development of novel treatments for autoimmune diseases. The definitive agreement outlines AbbVie’s acquisition of Landos, a clinical-stage biopharmaceutical company renowned for its innovative approach to creating oral therapeutics for […]
In a significant move for the biopharmaceutical industry, LENZ Therapeutics, Inc. (Nasdaq: LENZ), a trailblazer in developing innovative treatments for presbyopia, announced the successful completion of its merger with Graphite Bio, Inc. This strategic alliance ushers in a new era of healthcare solutions, focusing on the first aceclidine-based eye drop to enhance near vision for […]
